pH-sensitive nanoliposomes for passive and CXCR-4-mediated marine yessotoxin delivery for cancer therapy

Yessotoxin (YTX), a marine-derived drug, was encapsulated in PEGylated pH-sensitive nanoliposomes, covalently functionalized (strategy I) with SDF-1α and by nonspecific adsorption (strategy II), to actively target chemokine receptor CXCR-4. Cytotoxicity to normal human epithelial cells (HK-2) and pr...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2022-04, Vol.17 (10), p.717-739
Main Authors: Vieira, Ana Mg, Silvestre, Oscar F, Silva, Bruno Fb, Ferreira, Celso Jo, Lopes, Ivo, Gomes, Andreia C, Espiña, Begoña, Sárria, Marisa P
Format: Article
Language:English
Subjects:
anticancer activity
CXCR-4-targeting
dinoflagellates
passive targeting
pH-sensitive nanoliposomes
prostate and breast cancer treatment
yessotoxin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Yessotoxin (YTX), a marine-derived drug, was encapsulated in PEGylated pH-sensitive nanoliposomes, covalently functionalized (strategy I) with SDF-1α and by nonspecific adsorption (strategy II), to actively target chemokine receptor CXCR-4. Cytotoxicity to normal human epithelial cells (HK-2) and prostate (PC-3) and breast (MCF-7) adenocarcinoma models, with different expression levels of CXCR-4, were tested. Strategy II exerted the highest cytotoxicity toward cancer cells while protecting normal epithelia. Acid pH-induced fusion of nanoliposomes seemed to serve as a primary route of entry into MCF-7 cells but PC-3 data support an endocytic pathway for their internalization. This work describes an innovative hallmark in the current marine drug clinical pipeline, as the developed nanoliposomes are promising candidates in the design of groundbreaking marine flora-derived anticancer nanoagents.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2022-0010